EGFR and cancer: The rationale beyond this “rechallenge” strategy is that, after disease progression to first line EGFR-based chemotherapy, a treatment “holiday” from anti-EGFR drugs results in RAS mutant cancer cell decay, restoring the sensitivity of cancer cells to cetuximab or panitumumab [16,17,18].